ALX Oncology (ALXO) Projected to Post Earnings on Thursday

ALX Oncology (NASDAQ:ALXO) is expected to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect ALX Oncology to post earnings of ($0.72) per share for the quarter.

ALX Oncology Stock Up 1.0 %

Shares of NASDAQ:ALXO opened at $1.06 on Thursday. ALX Oncology has a 1 year low of $0.96 and a 1 year high of $17.83. The company has a market cap of $55.91 million, a PE ratio of -0.36 and a beta of 0.96. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The stock’s 50-day moving average is $1.47 and its 200 day moving average is $1.68.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Friday, January 24th. Jefferies Financial Group downgraded ALX Oncology from a “buy” rating to a “hold” rating and reduced their target price for the stock from $12.00 to $2.00 in a report on Thursday, December 19th. UBS Group reduced their target price on ALX Oncology from $4.00 to $2.20 and set a “buy” rating on the stock in a report on Monday, January 27th. Finally, HC Wainwright reduced their target price on ALX Oncology from $25.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, January 24th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $3.05.

Insider Transactions at ALX Oncology

In other ALX Oncology news, Director Rekha Hemrajani acquired 30,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were acquired at an average cost of $1.55 per share, with a total value of $46,500.00. Following the transaction, the director now owns 33,000 shares of the company’s stock, valued at $51,150. The trade was a 1,000.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 14,443 shares of company stock valued at $23,309 in the last ninety days. 33.40% of the stock is currently owned by corporate insiders.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.